Benzyl isothiocyanate Cancer Research Results

BITC, Benzyl isothiocyanate: Click to Expand ⟱
Features:

Benzyl isothiocyanate Benzyl isothiocyanate (BITC) is a naturally occurring aromatic isothiocyanate and electrophilic organosulfur phytochemical generated from the glucosinolate glucotropaeolin by myrosinase-mediated hydrolysis. Isothiocyanates (pid 476) is its parent chemical class. Natural dietary sources include nasturtium, garden cress, papaya and other plants containing benzyl glucosinolate. BITC has substantial mechanistic and animal anticancer evidence distinct from other isothiocyanates, particularly involving mitochondrial ROS generation, apoptosis, cell-cycle arrest and suppression of STAT3-dependent tumor signaling. It is not an approved anticancer drug and currently lacks convincing human cancer efficacy data.

Primary mechanisms (ranked):

  1. Mitochondrial respiratory-chain disruption, particularly complex III inhibition, causing ↑ mitochondrial ROS and oxidative stress in susceptible cancer cells.
  2. Intrinsic apoptosis through mitochondrial membrane-potential loss, Bax/Bak activation, XIAP suppression and caspase activation.
  3. G2/M cell-cycle arrest through modulation of cyclin B1, CDK1, CDC25C and related mitotic regulators.
  4. STAT3 suppression with downstream ↓ HIF-1α, VEGF, MMPs and angiogenic/invasive signaling.
  5. Metabolic suppression, including inhibition of CNOT2/c-Myc/STAT3-dependent glycolytic signaling in hepatocellular carcinoma models.
  6. Migration, invasion and metastatic signaling ↓ through context-dependent modulation of EMT, Wnt/β-catenin, Rho-GTPases and related pathways.
  7. Autophagy modulation; BITC can induce ROS-dependent autophagy, although autophagy can be cytotoxic or cytoprotective depending on tumor model.
  8. Secondary NRF2 activation as an adaptive electrophilic/oxidative-stress response; this can increase cytoprotective signaling and is not uniformly anticancer.

Bioavailability / PK relevance: BITC is orally absorbed and extensively metabolized through glutathione conjugation and the mercapturic-acid pathway. Human studies demonstrate urinary excretion of BITC-derived mercapturic-acid metabolites, with one oral study recovering approximately 54% of administered BITC as the major urinary metabolite and most excretion occurring within approximately 10–12 hours. After consumption of benzyl-glucosinolate-containing nasturtium, BITC metabolites and protein conjugates have been detected in plasma, urine and breath. Free BITC exposure is limited by rapid metabolism, chemical reactivity and protein conjugation. Pharmacokinetic characterization at proposed therapeutic anticancer doses remains inadequate.

In-vitro vs systemic exposure relevance: Many anticancer experiments use BITC concentrations in the low-micromolar range, commonly approximately 2.5–10 µM. Some investigators describe low-micromolar concentrations as potentially plasma-achievable, but robust human pharmacokinetic data demonstrating sustained free BITC at concentrations used in cancer-cell experiments are lacking. Consequently, direct translation of prolonged in-vitro exposure to oral human dosing remains uncertain. Protein binding/conjugation and rapid mercapturic-acid metabolism further reduce freely available BITC.

Clinical evidence status: Preclinical. There is extensive cancer-cell evidence and multiple animal studies demonstrating tumor-growth, angiogenesis and metastasis suppression. Human studies establish dietary absorption and metabolism but do not establish anticancer efficacy. No convincing completed clinical trial of BITC itself as a cancer treatment or chemopreventive intervention was identified. BITC should therefore be distinguished from phenethyl isothiocyanate (PEITC), which has entered human cancer-prevention trials.

Safety / translation: Dietary exposure and use as a food flavouring are substantially different from pharmacologic anticancer dosing. JECFA concluded that BITC presented no safety concern at current flavouring-use exposure, but concentrated therapeutic exposure has not been adequately established as safe. BITC is highly electrophilic and concentrated material is an eye and respiratory irritant. Experimental genotoxic effects have been reported at concentrations or doses substantially above normal human dietary exposure. These findings support caution against extrapolating food-level safety to high-dose supplementation.

Benzyl Isothiocyanate Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial respiratory chain and ROS Complex III activity ↓; mitochondrial ROS ↑ ROS response often substantially lower in tested normal epithelial cells R Oxidative stress and initiation of apoptosis ↑ One of the best-supported proximal mechanisms. Mitochondrial DNA-deficient breast-cancer cells are markedly resistant to BITC-induced ROS and apoptosis.
2 Mitochondrial apoptosis Membrane potential ↓; Bax/Bak ↑; caspase-9 and caspase-3 ↑; XIAP ↓ Apoptosis generally ↓ relative to susceptible cancer cells in comparative models R/G Programmed cell death ↑ ROS occurs upstream of much of the apoptotic response. p53 is not universally required.
3 Cell-cycle control G2/M arrest ↑; cyclin B1 ↓; CDK1 ↓; CDC25C ↓ Growth arrest generally less pronounced in tested normal epithelial cells G Proliferation ↓ Repeatedly observed across breast, pancreatic, lung and other cancer models.
4 STAT3 signaling STAT3 activation ↓ Context-dependent R/G Survival, proliferation and angiogenic signaling ↓ Important convergence point in pancreatic cancer and more recent metabolic studies.
5 HIF-1α VEGF angiogenesis axis HIF-1α ↓; VEGF ↓; VEGFR2 signaling ↓; MMP-2 ↓ Context-dependent G Angiogenesis and invasion ↓ Supported by pancreatic cancer cell, ex-vivo and mouse-tumor experiments and linked mechanistically to STAT3 suppression.
6 Glycolysis and CNOT2 c-Myc STAT3 CNOT2/c-Myc/STAT3 signaling ↓; glycolytic activity ↓ Insufficient comparative data G Metabolic stress and apoptosis ↑ Recent hepatocellular-carcinoma evidence identifies suppression of glycolytic signaling as an important component of BITC-induced apoptosis.
7 JNK p38 MAPK stress signaling JNK ↑; p38 MAPK ↑ (ROS-dependent) Activation substantially weaker or absent in some normal epithelial models R Bax activation and apoptosis ↑ Functions downstream of BITC-induced mitochondrial oxidative stress in several models.
8 Migration invasion and EMT Migration ↓; invasion ↓; vimentin ↓; MMP signaling ↓ Insufficient comparative data G Metastatic phenotype ↓ Supported in head-and-neck, pancreatic, breast and glioma models.
9 Wnt β-catenin signaling ↓ (model-dependent) Insufficient comparative data G Tumor growth and metastasis ↓ Supported particularly by murine mammary carcinoma studies; probably contextual rather than a universal BITC mechanism.
10 Autophagy ↑ (context-dependent) Insufficient comparative data G Stress adaptation or cell death ROS can initiate autophagy. In some prostate-cancer models autophagy is protective, because inhibition of autophagy increases BITC-induced apoptosis.
11 NRF2 oxidative-stress response NRF2 ↑ (secondary; context-dependent) NRF2 ↑ expected as electrophilic stress response R/G Cytoprotective antioxidant response ↑ BITC can activate NRF2 through canonical and non-canonical mechanisms. This may counterbalance ROS-mediated cytotoxicity rather than represent a primary anticancer mechanism.
12 Chemosensitization Cisplatin response ↑ in selected models Insufficient data G Drug-induced apoptosis ↑ Preclinical evidence includes sensitization of head-and-neck squamous carcinoma cells to cisplatin. Clinical confirmation is absent.
13 Clinical Translation Constraint Potentially active at low-micromolar experimental exposure High-dose safety incompletely defined G Clinical applicability uncertain Rapid metabolism, electrophilic protein binding, uncertain therapeutic human PK, formulation limitations and lack of BITC cancer trials currently restrict translation.

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr



Scientific Papers found: Click to Expand⟱
9231- ITCs,  Cisplatin,  AITC,  BITC,    Isothiocyanates inhibit the cisplatin-induced apoptosis and inflammation in human kidney HEK-293 cells
- in-vitro, Nor, HEK293
*ROS↓, *NO↓, *chemoP↑, *MAPK↓, *Bax:Bcl2↓, *Apoptosis↓, *RenoP↑,

Showing Research Papers: 51 to 51 of 51
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 51

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ARE↑, 1,   GPx4↓, 1,   GSH↓, 4,   HO-1↑, 1,   Iron↑, 1,   lipid-P↑, 1,   MDA↑, 1,   NRF2↑, 2,   ROS?, 1,   ROS↓, 1,   ROS↑, 12,   Trx↑, 2,   TrxR↑, 1,   TrxR1↑, 1,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 1,   CDC25↓, 4,   compI↓, 1,   compIII↓, 4,   compIV↓, 1,   ETC↓, 1,   mtDam↑, 1,   OCR↓, 1,   OXPHOS↓, 1,   SDH↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GlucoseCon↓, 1,   Glycolysis↓, 1,   GSK‐3β↑, 1,   HK2↓, 1,   PDK1 / PDPK1↓, 1,   PKM2↓, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

AIF↑, 1,   APAF1↑, 2,   Apoptosis?, 1,   Apoptosis↑, 14,   BAD↑, 1,   BAX↑, 5,   Bcl-2↓, 5,   Bcl-xL↓, 3,   BIM↑, 1,   Casp↑, 1,   Casp3↑, 5,   cl‑Casp3↑, 5,   proCasp3↓, 1,   Casp7↑, 1,   cl‑Casp7↑, 1,   Casp8↑, 1,   cl‑Casp8↑, 2,   Casp9↑, 2,   cl‑Casp9↑, 3,   Cyt‑c↑, 4,   Ferroptosis↑, 1,   IAP1↓, 1,   iNOS↓, 2,   MDM2↑, 1,   p38↓, 1,   survivin↓, 3,   TumCD↑, 2,   XIAP↓, 6,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 3,   p‑Akt↓, 1,   cMET↓, 1,   p‑CREB↑, 1,   EGFR↓, 1,   ERK↓, 1,   p‑ERK↓, 1,   p‑ERK↑, 2,   GRB2↓, 2,   HER2/EBBR2↓, 1,   JAK2↓, 1,   JNK↑, 2,   p‑JNK↓, 1,   MAPK↑, 1,   MST1R↓, 1,   mTOR↓, 4,   PI3K↓, 2,   PKCδ↓, 2,   PTEN↑, 1,   RAS↓, 2,   STAT3↓, 5,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   cMyc↓, 1,   DNMTs↓, 1,   FOXO1↓, 1,   FOXO3↓, 1,   H3↝, 1,   H4↝, 1,   HDAC↓, 2,   HDAC1↓, 2,   HDAC3↓, 2,   HDAC6↓, 1,   OCT4↓, 1,   SOX2↓, 1,   tumCV↓, 4,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 6,   P53↑, 3,   p‑P53↑, 1,   cl‑PARP↑, 4,   proPARP↓, 1,   PCNA↓, 3,   Telomerase↓, 2,   γH2AX↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 3,   CDK2↓, 3,   CDK4↓, 3,   CDK6↓, 1,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 2,   Ki-67↓, 6,   P21↓, 1,   P21↑, 2,   p27/CDKN1B↑, 1,   TumCCA↓, 1,   TumCCA↑, 16,   WEE1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cFos↓, 1,   CSCs↓, 4,   Ki-67↓, 6,   Nanog↓, 1,   NOTCH↑, 1,   NOTCH2↑, 1,   STAT1↓, 1,   TumCG↓, 10,   TumCP↓, 7,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   Ca+2↑, 1,   Ca+2↝, 1,   E-cadherin↑, 4,   EMT↓, 3,   FAK↓, 1,   Fibronectin↓, 1,   MMP2↓, 9,   MMP7↓, 1,   MMP9↓, 6,   PAI-1/SERPINE1↑, 1,   Rho↓, 1,   Slug↓, 1,   Snail↓, 2,   TGF-β↓, 1,   TIMP1↓, 2,   TIMP2↑, 1,   TumCI↓, 8,   TumCMig↓, 7,   TumMeta↓, 4,   uPA↓, 3,   uPAR↓, 1,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 6,   CD31/PECAM-1↓, 4,   Hif1a↓, 2,   VEGF↓, 5,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 7,   OCLN↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD44↓, 1,   COX2/PTGS2↓, 1,   CXCR4↓, 3,   IL6↓, 2,   Inflam↓, 1,   NF-kB?, 1,   NF-kB↓, 4,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   SXR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   ChemoSen↑, 3,   CYP3A4↓, 1,   Dose↑, 1,   Dose↝, 4,   eff↓, 3,   eff↑, 3,   eff↝, 2,   P450↓, 1,   RadioS↑, 3,   selectivity↑, 9,   selectivity↝, 1,   Synergy↑, 8,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   EGFR↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 2,   LDH↓, 1,   Polyps↓, 1,   Tumccf↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiTum↑, 3,   chemoPv↑, 2,   Risk↓, 4,   TGFβR1↓, 1,   TumNum↓, 3,   TumVol↓, 1,   TumW↓, 1,   Weight∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr?, 1,   Ingr↝, 2,  
Total Targets: 204

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 2,   GSTs↑, 1,   HO-1↑, 3,   MDA↓, 2,   MPO↓, 2,   NQO1↑, 3,   NRF2↑, 3,   ROS↓, 3,   ROS↑, 1,   ROS⇅, 1,   SOD↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

NADPH↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Bax:Bcl2↓, 1,   Casp3↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

MAPK↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑4E-BP1↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,   NO↑, 1,  

Barriers & Transport(tgid=15) ⓘ

GastroP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD40↓, 1,   DEFB1↑, 1,   IL10↓, 1,   Inflam↓, 2,   IP-10/CXCL-10↓, 1,   NF-kB↓, 1,   PGE2↑, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   BioAv↝, 1,   Dose?, 1,   Dose↝, 1,   eff↑, 5,  

Functional Outcomes(tgid=23) ⓘ

antiAll↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   RenoP↑, 1,   toxicity↝, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 3,   GutMicro∅, 1,  
Total Targets: 46

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:530  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page